☆ 4.2 Article

PD-L1 Expression in Different Segments and Histological Types of Ovarian Cancer According to Lymphocytic Infiltrate

MEDICINA-LITHUANIA (2021)

Related references

Note: Only part of the references are listed.

Article Immunology

Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+T-lymphocytes predicts disease-free survival

Akriti Bansal et al.

Summary: In this study, the expression of PD-L1 immune checkpoint inhibitor in high-grade serous carcinoma (HGSC) ovary was evaluated, revealing a linear correlation with CD4+ and CD8+ TIL levels. Higher PD-L1 expression was observed in patients who underwent neoadjuvant chemotherapy, suggesting a potential association with adaptive immune evasion.

APMIS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients

Anna Pawlowska et al.

Summary: The study highlights the significant role of the PD-1/PD-L1/PD-L2 axis in ovarian cancer pathogenesis, with a focus on the clinical importance of PD-L1/PD-L2 expression in the OC environment. Elevated levels of sPD-L1 in peritoneal fluid were found to be associated with shorter survival in OC patients, indicating a potential hallmark of immune regulation in this disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Multidisciplinary Sciences

Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation

Sandeep Kumar Parvathareddy et al.

Summary: This study found significant differences in PD-L1 expression between primary epithelial ovarian cancer (EOC) and peritoneal metastasis, with the latter being associated with adverse prognostic factors. The findings suggest that assessment of PD-L1 as a potential biomarker for predicting response to anti-PD-L1 therapy may require analysis of metastatic lesions.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Oncology

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis

Chen Zhang et al.

Summary: Our meta-analysis of 55 studies found that high PD-L1 expression is not significantly associated with overall survival, progression-free survival, recurrence-free survival, cancer-specific survival, and disease-free survival in gynecological cancers. However, subgroup analysis revealed that high PD-L1 expression may be correlated with a shorter overall survival in some cases. Additionally, PD-L1 positivity was associated with certain clinical parameters and could potentially predict response to anti-PD-1/PD-L1 treatment.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients

Alessandra Battaglia et al.

Summary: PD-1/PD-L1 axis blockade immunotherapy relies on assessing tumour PD-L1 status, but spatial heterogeneity may impact predictive value. This study identified PD-L1+ circulating tumor-derived microvesicles in high grade serous ovarian cancer patients for the first time, suggesting a novel approach for patient stratification in immunotherapy.

CANCERS (2021)

Add to Collection

Article Multidisciplinary Sciences

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome

Christine Bekos et al.

Summary: This study examined the infiltration rates of PD-1 and PD-L1 expressing tumor infiltrating leucocytes in primary ovarian tumor tissue and metastatic intraperitoneal implants, and found that high PD-1 expression among TILs in peritoneal metastases was associated with favorable overall survival, while high PD-L1 expression in TILs was linked to poor overall survival. Combining both factors in peritoneal metastases revealed an unfavorable prognosis. Primary ovarian tumor tissue and intraperitoneal metastatic tissues in EOC may have different immune evasion strategies. These findings are crucial for predicting patients' response to immunotherapy through biomarker assessment.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Oncology

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives

Brigida Anna Maiorano et al.

Summary: Ovarian cancer (OC) is a leading cause of cancer-related deaths in women, with high recurrence rates in the advanced disease setting. Clinical trials of immune checkpoint inhibitors (ICIs) in OC have shown poor outcomes in terms of patient response and survival, leading to early termination of some studies. Combining ICIs with other drugs targeting different pathways may enhance efficacy, and the search for predictive biomarkers for ICIs response is crucial for patient selection.

CANCERS (2021)

Add to Collection

Article Oncology

Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC)

Mayada Saad Farrag et al.

Summary: The study investigated the expression of PD-L1 and CD8 TILs in ovarian HGSC through immunohistochemistry, and the results were correlated with patient prognosis. Expression of PD-L1 was associated with CD8 TILs expression and was significantly linked to disease-free survival, suggesting a potential therapeutic target for patients with ovarian HGSC.

JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Article Oncology

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer

Changxin Wan et al.

Summary: This study demonstrates that the efficacy of immune therapies in high-grade serous ovarian cancer is driven by inducing state changes in NK cells and specific subsets of T cells. The results suggest that immune therapies, such as BRD1 inhibitors, capable of inducing such cellular state changes may have increased effectiveness in treating HGSC.

CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Cancer statistics, 2020

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Article Pathology

PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma

Laura Martin de la Fuente et al.

VIRCHOWS ARCHIV (2020)

Add to Collection

Article Pathology

PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-Ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma

Hao Chen et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)

Add to Collection

Article Immunology

PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer

Brian Diskin et al.

NATURE IMMUNOLOGY (2020)

Add to Collection

Review Oncology

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?

Klaus Pietzner et al.

JOURNAL OF GYNECOLOGIC ONCOLOGY (2018)

Add to Collection

Article Immunology

Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer

Qiaohong Wang et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2017)

Add to Collection

Article Oncology

Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer

Xinxin Zhu et al.

JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)

Add to Collection

Review Multidisciplinary Sciences

Elements of cancer immunity and the cancer-immune set point

Daniel S. Chen et al.

NATURE (2017)

Add to Collection

Article Oncology

PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens

Jonas J. Heymann et al.

CANCER CYTOPATHOLOGY (2017)

Add to Collection

Review Oncology

The immunobiology of myeloid-derived suppressor cells in cancer

Morteza Motallebnezhad et al.

TUMOR BIOLOGY (2016)

Add to Collection

Article Oncology

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

Silvia Darb-Esfahani et al.

ONCOTARGET (2016)

Add to Collection

Article Oncology

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer

John R. Webb et al.

GYNECOLOGIC ONCOLOGY (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types

Giosue Scognamiglio et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)

Add to Collection

Review Oncology

Tumor infiltrating lymphocytes in ovarian cancer

Phillip P. Santoiemma et al.

CANCER BIOLOGY & THERAPY (2015)

Add to Collection

Review Oncology

Classifying Cancers Based on T-cell Infiltration and PD-L1

Michele W. L. Teng et al.

CANCER RESEARCH (2015)

Add to Collection

Article Oncology

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

A. D'Incecco et al.

BRITISH JOURNAL OF CANCER (2015)

Add to Collection

Article Oncology

Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients

Johannes Landskron et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)

Add to Collection

Meeting Abstract Oncology

Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers.

Kyle Strickland et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

Wei-Ting Hwang et al.

GYNECOLOGIC ONCOLOGY (2012)

Add to Collection

Article Pathology

Construction of High-Density Tissue Microarrays at Low Cost by Using Self-Made Manual Microarray Kits and Recipient Paraffin Blocks

Chang Hwan Choi et al.

KOREAN JOURNAL OF PATHOLOGY (2012)

Add to Collection

Article Multidisciplinary Sciences

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Junzo Hamanishi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.